SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

Uveitis (inflammation of the middle layer of the eye)

When treated with Wobenzym® PS (Phlogenzym), 60% of patients with anterior uveitis were improved within about 17 days. I believe this data can be used to treat posterior uveitis based on the ability of Wobenzym to decrease TNF-alpha levels (a pro-inflammatory cytokine), and the current trend to use anti-TNF alpha antibodies to treat posterior uveitis.
Wobenzym® has shown some effectiveness in treating
Behcet's Disease, in which uveitis is a common presentation. Behcet’s may cause either anterior uveitis (inflammation in the front of the eye) or posterior uveitis (inflammation in the back of the eye), and sometimes causes both at the same time.
Anterior uveitis results in pain, blurry vision, light sensitivity, tearing, or redness of the eye. Posterior uveitis may be more dangerous and vision–threatening because it often causes fewer symptoms while damaging a crucial part of the eye — the retina.
                                          
From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND
                                           Read the special section:
EYES, EARS, NOSE & THROAT CONDITIONS & WOBENZYM®

What the literature says about Systemic Enzyme Support and:

Uveitis

When treated with Wobenzym® PS (Phlogenzyum),  60% of patients with anterior uveitis were improved within about 17 days. I believe this data can be used to treat posterior uveitis based on the ability of Wobenzym to decrease TNF-alpha levels (a pro-inflammatory cytokine), and the current trend to use anti-TNF alpha antibodies to treat posterior uveitis.
It should also be noted that Wobenzym has shown some effectiveness in treating
Behcet's Disease, in which uveitis is a presentation.
 

Our first experience with utilisation of hydrolytic enzymes in arterior uveitis.

Porubská M. Department of Ophthalmology, Institute of Respiratory Diseases, Nový Smokovec, Slovakia. Rheumatologia 2000, Roč. 14, č. 2, str. 65-69. (3-14-1)
 
Summary: Objective: New therapeutic methods with lower adverse effects than those of corticosteroids and immunosuppressive are seeked for in the treatment of anterior uveitis. The aim of the monitoring was assess the efficacy of Wobenzym and Phlogenzym in the anterior uveitis activity and to compare their therapeutic effect with the effect of high doses of both the system and parabulbar application of corticosteroids and/or immunosuppressives.Methods: A group of 29 hospitalized patients with the high activity of anterior acute and chronic uveitis received enzyme preparations for 8 weeks and paralelly, decrease of inflammatory activity was evaluated.Results: In a group of patients with anterior acute uveitis mostly associated with ankylosing spondylitis, inflammatory cells from the eye anterior chamber in patients treated with hydrolytic enzymes got absorbed on average in 20 days compared to 27 days in the control group. In the patients with chronic anterior uveitis mostly associated with juvenile chronic arthritis all the inflammatory cells in 50 % of the patients treated with Wobenzym got absorbed on average in 20.3 days, in 60 % of the patients treated with Phlogenzym they got absorbed on average in 17.3 days with the most persisting effect and in the control group in 37 % of 'the patients on average in 30 days. In the patients receiving enzymes. Fibrín and Tyndal got absorbed in 1 day, in the control group in 4-5 days.Conclusion: The results suggest that, utilization of hydrolytic enzymes makes possible to lower the dosage of corticoids and contributes to shorter time needed for inhibition of the uveitis inflammatory activity, important especially in children with JCA. The best results were observed in administration of Phlogenzym.
Key words: hydrolytic enzymes, corticosteroids, anterior chamber, uveitis.